For research use only. Not for therapeutic Use.
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)[1].
Catalog Number | I042163 |
CAS Number | 2275727-74-5 |
Purity | ≥95% |
Reference | [1]. Kim SB, et, al. 887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). VOLUME 32, SUPPLEMENT 5, S797, SEPTEMBER 01, 2021. |